Investigating how certain antibodies may prevent the reactivation of herpes simplex virus type 1.
Official title: Does Antibody-Dependent Intracellular Neutralization Limit HSV-1 Reactivation?
Funded at Dartmouth College · NIH-10738808 · Data updated 2026-11-12
This study is looking at how certain antibodies in your body can help keep the herpes virus from coming back and causing problems, and it aims to find new ways to manage HSV-1 infections.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dartmouth College NIH-funded |
| Lab location | 1 site (Hanover, United States) |
| Project start | November 10, 2022 |
| Project end | October 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $246,000 |
| NIH project number | 5R21AI173941-02 |
| Project ID | NIH-10738808 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with a history of herpes simplex virus infections, particularly those experiencing recurrent outbreaks.
✕Less likely to help
Patients who have never been infected with herpes simplex virus or those with other unrelated viral infections may not benefit from this research.
What this research studies
This research explores the role of non-neutralizing antibodies (nNAbs) in controlling herpes simplex virus type 1 (HSV-1) reactivation. It focuses on a mechanism called antibody-dependent intracellular neutralization (ADIN), where these antibodies can bind to the virus inside cells and help eliminate it. The study aims to understand how these antibodies access the cytosol of cells and their potential to prevent viral reactivation, which is crucial for protecting neurons from damage. By examining this process, the research seeks to uncover new strategies for managing HSV-1 infections.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for preventing HSV-1 reactivation, reducing the risk of complications associated with the virus.
How similar studies have gone: While the concept of antibody-dependent intracellular neutralization is relatively novel, preliminary findings suggest that similar approaches have shown promise in other viral infections.
Where this research is happening
-
Dartmouth College
Hanover, United States Active
Researchers
- Principal investigator: Leib, David a — Dartmouth College
- Study coordinator: Leib, David a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.